

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|--|
| (51) International Patent Classification 6: C12N 15/12, 15/85, 5/10, C07K 14/47, A61K 38/17 | | A2 | (11) International Publication Number: WO 97/00319 (43) International Publication Date: 3 January 1997 (03.01.97) |
| (21) International Application Number: PCT/GB96/01388 (22) International Filing Date: 11 June 1996 (11.06.96) | | (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIGO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| (30) Priority Data: 9511935.0 13 June 1995 (13.06.95) GB | | Published <i>Without international search report and to be republished upon receipt of that report.</i> | |
| (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): BROWNE, Michael, Joseph (GB/GB); (GB). CHAPMAN, Conrad, Gerald (GB/GB); (GB). CLINKENBEARD, Helen, Elizabeth (GB/GB); (GB). ROBINSON, Jeffrey, Hugh (GB/GB); SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). | | | |
| (74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB). | | | |
| (54) Title: CHIMERIC LEPTIN FUSED TO IMMUNOGLOBULIN DOMAIN AND USE | | | |
| (57) Abstract | | | |
| <p>Chimeric leptin which are proteins comprising leptin or a mutant or a variant thereof fused to a human immunoglobulin domain. One favoured immunoglobulin domain is the human immunoglobulin Fc domain. The chimeric derivatives of leptin have, despite their large molecular size, good pharmacological activity combined with prolonged clearance rates. These derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity or diseases and conditions associated with obesity such as atherosclerosis, hypertension and type II diabetes.</p> | | | |
| BEST AVAILABLE COPY | | | |